MX394222B - Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). - Google Patents

Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).

Info

Publication number
MX394222B
MX394222B MX2017006113A MX2017006113A MX394222B MX 394222 B MX394222 B MX 394222B MX 2017006113 A MX2017006113 A MX 2017006113A MX 2017006113 A MX2017006113 A MX 2017006113A MX 394222 B MX394222 B MX 394222B
Authority
MX
Mexico
Prior art keywords
growth hormone
human growth
hgh
new polymeric
polymeric prodrugs
Prior art date
Application number
MX2017006113A
Other languages
English (en)
Other versions
MX2017006113A (es
Inventor
Alina Hermann
Anna Splanemann
Evelyn Exner
Rasmussen Grethe Nørskov
Harald Rau
Joachim Zettler
Nina Schubert
Steen Jensen
Thomas Kurpiers
Thomas Wegge
Torben Lessmann
Original Assignee
Ascendis Pharma Endocrinology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX394222(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ascendis Pharma Endocrinology Div A/S filed Critical Ascendis Pharma Endocrinology Div A/S
Publication of MX2017006113A publication Critical patent/MX2017006113A/es
Publication of MX394222B publication Critical patent/MX394222B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G17/00—Cultivation of hops, vines, fruit trees, or like trees
    • A01G17/005—Cultivation methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G2/00—Vegetative propagation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
    • A01G7/00—Botany in general
    • A01G7/06—Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterized by the type of post-polymerisation functionalisation
    • C08G2650/06—Epoxy-capping

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Ecology (AREA)
  • Forests & Forestry (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un profármaco polimérico de la hormona del crecimiento humano y formulaciones farmacéuticas secas, líquidas y reconstituidas que comprenden el profármaco. Además se refiere a su uso como medicamentos para el tratamiento de enfermedades las cuales se pueden tratar con la hormona del crecimiento y a métodos de tratamiento. También se refiere a métodos de aplicación de tal profármaco polimérico de la hormona del crecimiento humano o formulación farmacéutica.
MX2017006113A 2014-11-18 2015-11-17 Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). MX394222B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14193603 2014-11-18
PCT/EP2015/076813 WO2016079114A1 (en) 2014-11-18 2015-11-17 Novel polymeric hgh prodrugs

Publications (2)

Publication Number Publication Date
MX2017006113A MX2017006113A (es) 2017-10-16
MX394222B true MX394222B (es) 2025-03-24

Family

ID=51951624

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006113A MX394222B (es) 2014-11-18 2015-11-17 Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
MX2022009155A MX2022009155A (es) 2014-11-18 2017-05-10 Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022009155A MX2022009155A (es) 2014-11-18 2017-05-10 Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).

Country Status (27)

Country Link
US (3) US10799563B2 (es)
EP (3) EP3653227B9 (es)
JP (6) JP6783782B2 (es)
KR (3) KR20250059541A (es)
AU (3) AU2015348633C1 (es)
CA (1) CA2968282A1 (es)
CY (2) CY1123963T1 (es)
DK (2) DK3237014T5 (es)
ES (2) ES2947818T3 (es)
FI (2) FI3237014T3 (es)
FR (1) FR22C1029I2 (es)
HR (1) HRP20210400T4 (es)
HU (2) HUE053855T2 (es)
IL (2) IL251906B2 (es)
LT (2) LT3653227T (es)
LU (1) LUC00256I2 (es)
MX (2) MX394222B (es)
NL (1) NL301172I2 (es)
NO (1) NO2022014I1 (es)
PL (1) PL3653227T6 (es)
PT (1) PT3653227T (es)
RS (1) RS61734B2 (es)
RU (1) RU2718664C2 (es)
SG (2) SG11201703870UA (es)
SI (1) SI3653227T1 (es)
SM (1) SMT202100172T1 (es)
WO (1) WO2016079114A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2279007T3 (en) 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
US10799563B2 (en) 2014-11-18 2020-10-13 Ascendis Pharma Endocrinology Division Polymeric hGH prodrugs
PL3220892T3 (pl) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Postacie dawkowane długo działającego hormonu wzrostu
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
NZ751746A (en) 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
BR112020019639A2 (pt) * 2018-03-28 2021-01-05 Ascendis Pharma Oncology Division A/S Conjugados de il-2
US20210008168A1 (en) 2018-03-28 2021-01-14 Ascendis Pharma A/S Conjugates
EP3906065B1 (en) 2019-01-04 2025-04-30 Ascendis Pharma Oncology Division A/S Prr agonist for use in the treatment of cancer
JP2022516314A (ja) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス 自然免疫アゴニストのための持続性局所性薬物レベル
EP3906060A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Conjugates of pattern recognition receptor agonists
AU2020204786A1 (en) 2019-01-04 2021-06-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
SG11202108735QA (en) * 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
IL298642A (en) 2020-06-03 2023-01-01 Ascendis Pharma Oncology Div A/S il-2 sequences and uses thereof
WO2022207798A1 (en) 2021-04-01 2022-10-06 Ascendis Pharma A/S Use of long-acting growth hormone for treating inflammation-induced diseases
WO2023086103A1 (en) * 2021-11-12 2023-05-19 Beckman Coulter, Inc. Novel formulation for drying of polymer dye conjugated antibodies

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
IL78930A0 (en) 1985-07-29 1986-09-30 Abbott Lab Lyophilized emulsion compositions for parenteral administration
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5179080A (en) 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
EP0495445A1 (en) 1991-01-16 1992-07-22 Takeda Chemical Industries, Ltd. Dual-chamber type syringe
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
IL101007A (en) 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
SE501808C2 (sv) 1993-11-26 1995-05-22 Hans Lundstroem Anordning vid en box
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US6011197A (en) * 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
US5971953A (en) 1998-01-09 1999-10-26 Bachynsky; Nicholas Dual chamber syringe apparatus
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
JP4361710B2 (ja) 2000-04-19 2009-11-11 ジェネンテック・インコーポレーテッド 徐放製剤
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
HRP20040448A2 (en) 2001-11-20 2006-02-28 Pharmacia Corporation Method for detecting cells with numerical chromosomal abnormalities
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7144978B2 (en) 2002-01-15 2006-12-05 Pan Asia Bio Co., Ltd. Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
WO2004019993A1 (en) 2002-08-30 2004-03-11 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
MXPA05005178A (es) 2002-11-15 2005-07-22 Hoffmann La Roche Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg).
US20040142870A1 (en) 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
EP1673464A2 (en) 2003-10-10 2006-06-28 Novo Nordisk A/S Conjugation of peptides
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
JP4950022B2 (ja) 2004-03-23 2012-06-13 コンプレックス バイオシステムズ ゲーエムベーハー 自壊性リンカーを有する高分子プロドラッグ
EP1579873A1 (en) * 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymeric prodrugs
EP1625855A1 (en) * 2004-08-13 2006-02-15 Complex Biosystems GmbH Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
WO2006071840A2 (en) 2004-12-22 2006-07-06 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
EP2284191A3 (en) 2004-12-22 2011-07-20 Ambrx, Inc. Process for the preparation of hGH
US7959600B2 (en) 2004-12-30 2011-06-14 Byeong S. Chang Container closure delivery system
US20080207505A1 (en) 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
JP2008531482A (ja) 2005-02-10 2008-08-14 ノボ ノルディスク アクティーゼルスカブ Ｃ末端がｐｅｇ化された成長ホルモン
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
US20100197573A1 (en) 2005-06-15 2010-08-05 Novo Nordisk Health Care Ag Transglutaminase Mediated Conjugation of Growth Hormone
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
WO2007025988A2 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
KR20150001844A (ko) 2006-01-24 2015-01-06 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
WO2008148839A2 (en) 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
HRP20110368T1 (hr) 2007-06-21 2011-06-30 Technische Universitt Mnchen Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
CN101980725B (zh) 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
EP2113256A1 (en) * 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
DK2279007T3 (en) * 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
JP2012519666A (ja) 2009-03-05 2012-08-30 アセンディス ファーマ エーエス インターフェロンアルファ担体プロドラッグ
WO2011003234A1 (zh) 2009-07-08 2011-01-13 深圳市掌网立体时代视讯技术有限公司 光学立体放映装置、系统及方法
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
ES2833035T3 (es) 2009-07-31 2021-06-14 Ascendis Pharma As Hidrogeles biodegradables insolubles en agua a base de polietilenglicol
DK2512450T3 (en) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Dry growth hormone composition transiently bound to a polymer carrier
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AU2011254564B2 (en) 2010-05-21 2014-03-27 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
CN104955472A (zh) 2012-10-17 2015-09-30 诺和诺德保健股份有限公司 用于生长激素递送的脂肪酸酰化的氨基酸
US10799563B2 (en) 2014-11-18 2020-10-13 Ascendis Pharma Endocrinology Division Polymeric hGH prodrugs
PL3220892T3 (pl) 2014-11-21 2022-01-31 Ascendis Pharma Endocrinology Division A/S Postacie dawkowane długo działającego hormonu wzrostu
WO2016109823A1 (en) 2015-01-02 2016-07-07 Amunix Operation Inc. Treatment of pediatric growth hormone deficiency with human growth hormone analogues
SG11202108735QA (en) 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Also Published As

Publication number Publication date
CY1123963T1 (el) 2022-05-27
FR22C1029I1 (fr) 2022-09-09
ES2947818T3 (es) 2023-08-21
IL251906B2 (en) 2024-04-01
FIC20220017I1 (fi) 2022-06-03
DK3237014T3 (da) 2023-05-30
US20170354716A1 (en) 2017-12-14
LUC00256I2 (es) 2025-03-04
IL251906B1 (en) 2023-12-01
ES2864415T3 (es) 2021-10-13
US20200390864A1 (en) 2020-12-17
SI3653227T1 (sl) 2021-04-30
EP3653227B1 (en) 2021-01-20
RU2017121203A3 (es) 2019-05-30
NZ769682A (en) 2024-09-27
SMT202100172T1 (it) 2021-05-07
JP2017535609A (ja) 2017-11-30
LT3653227T (lt) 2021-03-25
AU2015348633A1 (en) 2017-05-18
HRP20210400T1 (hr) 2021-04-16
US12133883B2 (en) 2024-11-05
PL3653227T3 (pl) 2021-07-05
CY2022013I1 (el) 2023-01-05
FR22C1029I2 (fr) 2023-04-14
WO2016079114A1 (en) 2016-05-26
US10799563B2 (en) 2020-10-13
EP3653227A1 (en) 2020-05-20
EP4218823A3 (en) 2023-11-15
RS61734B2 (sr) 2022-04-29
ES2864415T7 (es) 2022-05-12
KR20170084267A (ko) 2017-07-19
KR20250059541A (ko) 2025-05-02
NL301172I1 (nl) 2022-04-29
PL3653227T6 (pl) 2022-04-19
NL301172I2 (nl) 2022-06-16
AU2015348633C1 (en) 2021-02-11
JP7210683B2 (ja) 2023-01-23
JP2021020932A (ja) 2021-02-18
RU2017121203A (ru) 2018-12-19
EP3237014B1 (en) 2023-03-29
ES2864415T9 (es) 2023-05-23
IL307773A (en) 2023-12-01
CA2968282A1 (en) 2016-05-26
NO2022014I1 (no) 2022-05-12
EP3653227B9 (en) 2023-03-08
NZ731779A (en) 2021-11-26
KR20230152187A (ko) 2023-11-02
CY2022013I2 (el) 2023-01-05
EP3653227B3 (en) 2022-03-09
LTPA2022506I1 (es) 2022-06-10
DK3653227T3 (da) 2021-02-15
LTC3653227I2 (es) 2024-11-25
AU2020270494B2 (en) 2024-02-01
SG11201703870UA (en) 2017-06-29
SG10202105511RA (en) 2021-07-29
PT3653227T (pt) 2021-02-26
MX2017006113A (es) 2017-10-16
KR102608645B1 (ko) 2023-12-01
DK3653227T6 (da) 2022-04-11
HUS2200019I1 (hu) 2022-06-28
EP3237014A1 (en) 2017-11-01
JP2024054177A (ja) 2024-04-16
JP6783782B2 (ja) 2020-11-11
AU2020270494A1 (en) 2020-12-17
JP2022033787A (ja) 2022-03-02
US20250032587A1 (en) 2025-01-30
JP2023052300A (ja) 2023-04-11
BR112017009798A8 (pt) 2020-11-03
JP6982156B2 (ja) 2021-12-17
AU2024201227A1 (en) 2024-03-28
AU2015348633B2 (en) 2020-10-22
DK3653227T5 (da) 2023-08-21
HUE053855T2 (hu) 2021-07-28
JP7431355B2 (ja) 2024-02-14
JP2026041857A (ja) 2026-03-10
FI3237014T3 (fi) 2023-06-09
RU2718664C2 (ru) 2020-04-13
BR112017009798A2 (pt) 2017-12-19
JP7785109B2 (ja) 2025-12-12
HRP20210400T4 (hr) 2022-04-29
DK3237014T5 (da) 2024-10-14
RS61734B1 (sr) 2021-05-31
IL251906A0 (en) 2017-06-29
MX2022009155A (es) 2022-08-16
EP4218823A2 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
MX394222B (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
PT3383363T (pt) Formulações farmacêuticas tópicas para o tratamento de afeções relacionadas com inflamações
TW201613901A (en) New compounds
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EP3673899C0 (en) NASAL POWDER FORMULATION FOR THE TREATMENT OF HYPOGLYCEMIA
MX386702B (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
LT3168214T (lt) Pakeisti 2-tiokso-imidazolidin-4-onai ir jų spiro analogai, aktyvi priešvėžinė sudedamoji dalis, farmacinė kompozicija, medicininis paruošimas, prostatos vėžio gydymo būdas
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
PL3424499T3 (pl) Kompozycja farmaceutyczna do leczenia bólu neuropatycznego
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EP3344233A4 (en) TRANSDERMAL FORMULATIONS FOR THE DELIVERY OF DOXYCLYCLIN AND THEIR USE IN THE TREATMENT OF DOXYCLYCLIN-RELATED ILLNESSES AND SUFFERING
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
IL251555A0 (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
EP3639842A4 (en) Pharmaceutical composition containing gly-thymosin 4 (gly-t 4) for treatment of dry eye
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
EP3506906A4 (en) TOPICAL FORMULATIONS OF FENOLDOPAM FOR THE TREATMENT OF SKIN DISORDERS
EP3226883C0 (en) COMPOSITIONS FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA
EP3322435A4 (en) Pharmaceutical compositions useful for the treatment of tissue injury